Twist Bioscience Co. (NASDAQ:TWST) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $54.40.

Several brokerages recently weighed in on TWST. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the director now owns 16,641 shares in the company, valued at approximately $832,050. This represents a 23.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Dennis Cho sold 806 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. This represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,799 shares of company stock valued at $1,593,944 in the last quarter. 3.01% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience during the third quarter worth $34,000. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Twist Bioscience in the 4th quarter worth $43,000. GF Fund Management CO. LTD. purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at about $58,000. Finally, US Bancorp DE lifted its position in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $40.36 on Monday. The stock has a 50-day moving average price of $45.15 and a two-hundred day moving average price of $45.33. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market capitalization of $2.41 billion, a PE ratio of -11.94 and a beta of 2.15. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the firm posted ($0.75) earnings per share. The firm’s revenue was up 24.1% compared to the same quarter last year. Analysts expect that Twist Bioscience will post -2.12 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.